Phenomix Inks Licensing Deal with Mayo Clinic for Obesity Phenotype Blood Test
What You Should Know:
– Today, Phenomix Sciences announced the company has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes.
– The multi-level “omics” MyPhenome™ test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels. Its AI-driven algorithmic solution identifies four specific obesity phenotypes to give doctors the ability to prescribe more precise anti-obesity treatments.
– With the finalization of the CLIA lab underway, Phenomix anticipates launching the MyPhenome™ test before the end of 2021.
Guiding Treatment by Four Obesity Phenotypes